Mammen to depart J&J, leaving behind data science foundation

Seven new drug approvals, more than 30 label expansions and a deal-driven foundation in data science define the legacy that Mathai Mammen leaves at J&J after serving more than five years as the pharma’s EVP of pharmaceutical R&D.

Johnson & Johnson (NYSE:JNJ) announced Mammen’s departure late Monday. William Hait will serve as interim head of the Pharmaceutical R&D organization until new leadership is found.  Mammen will remain at least through year end to aid with the transition. J&J is initiating a search for his replacement...